ScreenerHero

OBXObsidian Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · obsidiantx.com
19.90USD-0.50%Mkt Cap: 1.23B $P/E: —

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.23B $
Enterprise Value276.37M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-100.61M $
Revenue/Share—
Last Price19.90 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees71
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.48
PEG—
EV/EBITDA-2.82
EV/Revenue—
P/S—
P/B-1.54
EPS (TTM)-1.56
EPS (Forward)-2.13
52W Range
14.5715% of range49.97
52W High49.97 USD
52W Low14.57 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE37.82%
ROA-113.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-90.39M $
CapEx (TTM)73.00K $
FCF Margin—
FCF Yield—
Net Debt-55.15M $
Net Debt/EBITDA0.56
Balance Sheet
Debt/Equity-0.02
Current Ratio4.21
Quick Ratio3.86
Book Value/Sh-13.0980 USD
Cash/Share793.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.50 USD
Upside (mean)+113.6%
Target Range42.00 USD – 43.00 USD
$42.00+113.6% to mean$43.00
# Analysts2
Ownership
Shares Out.61.77M
Float—
Insiders0.86%
Institutions27.49%
Technical
SMA 5022.50 (-11.6%)
SMA 20022.50 (-11.6%)
Beta2.64
S&P 52W Chg18.16%
Avg Vol (30d)110.49K
Avg Vol (10d)68.76K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—